Skip to content

Conflicting pharmacokinetic results when lopinavir and atazanavir are double-boosted with ritonavir

Four more Ranbaxy drugs on WHO pre-qualification list

UN meeting: commitment to universal treatment access slipping away at 11th hour, say advocates

1% of patients at French hospital develop rash after starting treatment with atazanavir

Study finds no link between efavirenz use and depression

MSF study says 3TC/d4T/NVP fixed-dose combination should be provided 'rapidly and without reservation' in resource-limited countries

Should patients with high viral loads and high CD4 cell counts start anti-HIV therapy? (corrected)

Generic version of abacavir approved for use by PEPFAR programmes

Twice-daily boosted fosamprenavir non-inferior to twice-daily Kaletra in treatment-naive